Publications by authors named "Richard Piekarz"

61Publications

Entinostat: a promising treatment option for patients with advanced breast cancer.

Future Oncol 2017 Jun 9;13(13):1137-1148. Epub 2017 Mar 9.

Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0526DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618943PMC
June 2017

CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio.

Clin Cancer Res 2015 May;21(10):2195-7

Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2555DOI Listing
May 2015

Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.

Clin J Oncol Nurs 2012 Apr;16(2):195-204

Medical Oncology Branch at Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1188/12.CJON.195-204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243910PMC
April 2012

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Blood 2011 Jun 25;117(22):5827-34. Epub 2011 Feb 25.

Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health/DHHS, 6130 Executive Blvd., Rockville, MD 20852, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2010-10-31
Publisher Site
http://dx.doi.org/10.1182/blood-2010-10-312603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112033PMC
June 2011

Clinical Toxicities of Histone Deacetylase Inhibitors.

Pharmaceuticals (Basel) 2010 Aug 26;3(9):2751-2767. Epub 2010 Aug 26.

Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ph3092751DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034096PMC
August 2010

Religious tradition and concern for the welfare of all living beings.

JAMA 2010 May;303(20):2033-4; author reply 2034

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2010.664DOI Listing
May 2010

Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Cell Cycle 2010 May 15;9(9):1830-8. Epub 2010 May 15.

Cell & Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.9.9.11543DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659113PMC
May 2010

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.

Haematologica 2009 Nov 16;94(11):1618-22. Epub 2009 Jul 16.

Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria 3002, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2009.008607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770976PMC
November 2009

Epigenetic modifiers: basic understanding and clinical development.

Clin Cancer Res 2009 Jun 9;15(12):3918-26. Epub 2009 Jun 9.

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2788DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946182PMC
June 2009

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.

Clin Cancer Res 2009 Feb;15(4):1496-503

Clinical Pharmacology Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-1215DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707030PMC
February 2009

Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?

Cancer J 2007 Mar-Apr;13(2):80-3

Molecular Therapeutics Section, Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e318063bd9fDOI Listing
June 2007

Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.

Cancer J 2007 Jan-Feb;13(1):30-9

Molecular Therapeutic Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1903, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31803c73ccDOI Listing
June 2007

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.

Clin Cancer Res 2006 Jun;12(12):3762-73

Center for Cancer Research and Cancer Therapeutics Evaluation Program, National Cancer Institute and National Heart Lung and Blood Institute, NIH, Bethesda, Maryland 20892-1903, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-2095DOI Listing
June 2006

Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).

Clin Cancer Res 2006 Mar;12(5):1547-55

Cancer Therapeutics Branch, Center for Cancer Research, NIH, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-1423DOI Listing
March 2006

Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.

J Chromatogr B Analyt Technol Biomed Life Sci 2004 Sep;809(1):81-6

Clinical Pharmacology Research Core, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S157002320400489
Publisher Site
http://dx.doi.org/10.1016/j.jchromb.2004.06.007DOI Listing
September 2004

A review of depsipeptide and other histone deacetylase inhibitors in clinical trials.

Curr Pharm Des 2004 ;10(19):2289-98

Cancer Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612043383980DOI Listing
August 2004

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.

Blood 2004 Jun 2;103(12):4636-43. Epub 2004 Mar 2.

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute/NIH, MSC 1903, 10 Center Drive, Building 10/Room 12C103, Bethesda, MD 20892-1903, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-09-3068DOI Listing
June 2004